More than 20 years ago, the American Association for Cancer Research and the Japanese Cancer Association held their first of eight joint conferences.
These meetings have been aimed at bringing outstanding American and Japanese researchers together with two goals. The first is to provide a forum for discussion of the latest advances in the broad field of cancer research, both translational/clinical and basic.
The second and equally important goal is to provide a mechanism for the interpersonal interactions which foster international collaborations. These conferences have been extremely successful in both areas and are tangible examples of the close relationship between the AACR and the JCA.
The Ninth Joint Conference continues to extend this tradition. The 12 conference sessions will feature outstanding speakers covering topics ranging from basic science to therapeutics, including prevention, epigenetics and other important areas. Thus, the conference will take a broad view of contemporary cancer research that is intended to be of interest to basic and clinical investigators.
The organization and timing of the platform and poster sessions have been designed to maximize interactions. The conference organizers believe that this meeting will catalyze many new collaborations, just as its predecessors have done.
ORGANIZING COMMITTEE:
Lynda Chin, The University of Texas MD Anderson Cancer Center, Houston, TX, USA (AACR)
Lisa M. Coussens, Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA (AACR)
Mari Kannagi, Tokyo Medical & Dental University, Tokyo, Japan (JCA)
Gou Young Koh, Korea Advanced Institute, Daejeon, Korea (Rep.) (JCA)
Sean J. Morrison, UT Southwestern Medical Center, Dallas, TX, USA (AACR)
Hitoshi Nakagama, National Cancer Center Research Institute, Tokyo, Japan (JCA)
Tomoki Naoe, Nagoya University Hospital, Nagoya, Japan (JCA)
Motoharu Seiki, University of Tokyo, Institute of Medical Science, Tokyo, Japan (JCA)
Jeffrey E. Settleman, Genentech Inc., South San Francisco, CA, USA (AACR)
Phillip A. Sharp, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA (AACR)
